Sacituzumab Govitecan in Hormone Receptor–Positive/Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer
University of California, San Francisco · UCSF Helen Diller Family Comprehensive Cancer Center · +15 more institutions
Abstract
PURPOSE Hormone receptor–positive (HR+) human epidermal growth factor receptor 2–negative (HER2–) endocrine-resistant metastatic breast cancer is treated with sequential single-agent chemotherapy with poor outcomes. Sacituzumab govitecan (SG) is a first-in-class antibody-drug conjugate with an SN-38 payload targeting trophoblast cell-surface antigen 2, an epithelial antigen expressed in breast cancer. METHODS In this global, randomized, phase III study, SG was compared with physician's choice chemotherapy (eribulin, vinorelbine, capecitabine, or gemcitabine) in endocrine-resistant, chemotherapy-treated HR+/HER2– locally recurrent inoperable or metastatic breast cancer. The primary end point was…
Citation impact
- FWCI
- 27.56
- Percentile
- 100%
- References
- 22
Authors
16- HSHope S. RugoCorresponding
University of California, San Francisco, UCSF Helen Diller Family Comprehensive Cancer Center
- ABAditya Bardia
Harvard University, Massachusetts General Hospital
- FMFrederik Marmé
Heidelberg University, University Hospital Heidelberg, University Medical Centre Mannheim
- JCJavier Cortés
Universidad Europea de Madrid
- PSPeter Schmid
Queen Mary University of London
Topics & keywords
- Medicine
- Metastatic breast cancer
- Internal medicine
- Vinorelbine
- Hazard ratio
- Oncology
- Breast cancer
- Chemotherapy
- Good health and well-being